CAIN CHRISTOPHER W. 4

What Happened Christopher W. Cain, a director of Damora Therapeutics, was granted a derivative award on March 23, 2026: options covering 37,313 shares (transaction code A). The filing reports $0 cash exchanged for the grant; this is an equity award (option) rather than an open-market buy or sale. The options vest in equal monthly installments through March 23, 2029, subject to continued service.

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (timely filing).
• Transaction type/code: Award/Grant (A) — derivative option covering 37,313 shares; reported amount $0.00.
• Vesting: Equal monthly installments through March 23, 2029, contingent on continued service (see footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• Beneficial ownership note: Cain holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC and states he will turn over any net cash/stock to those Fairmount Funds; Cain disclaims beneficial ownership of the option and underlying shares; Fairmount likewise disclaims beneficial ownership except for any pecuniary interest (see footnote F2).

Context This filing reflects a grant of options (a future right to purchase stock) rather than an immediate purchase or sale of shares. No exercise or sale is reported here, and because Cain disclaims beneficial ownership in favor of Fairmount-managed funds, this grant primarily documents a compensation/allocative arrangement rather than direct insider accumulation.